Development and Evaluation of a PH-dependent Sustained Release Tablet for Irritable Bowel Syndrome

Overview

Journal Drug Dev Ind Pharm

Publisher Informa Healthcare

Specialty Pharmacology

Date 2008 Nov 26

PMID 19031287

Citations 1

Authors

Shuang-Qing Zhang

Ziyaur Rahman

Sridhar Thumma

Michael A Repka

Guo-Hua Chen

San-ming Li

Affiliations

Soon will be listed here.

Abstract

The overall objective of this study was to develop a pH-dependent sustained release tablet formulation of a model drug, tegaserod maleate (TM), which is a poorly water soluble and acid labile drug in gastric milieu. The formulation's goal was to allow the dosage form to pass through the stomach intact, start disintegrating in the upper small intestine and slowly release the active in a controlled manner. Partition coefficient, contact angle and drug-excipient compatibility were investigated as part of the preformulation studies. A pH-dependent sustained release tablet was prepared using a combination of Eudragit L100 and Eudragit S100. The effects of solubilizer, disintegrant, binder, coating polymer concentration, pore former, and plasticizer on the drug release rate were determined. The results demonstrated that approximately 90% of the drug was released in a sustained release manner in the pH 6.8 phosphate buffer within 12 h while no drug was detected when subjected to drug release studies in 0.1 mol/L hydrochloric acid for 2 h. The drug release mechanism involved stress points and/or pore formation in the coated film. The coated tablets were stable at 40 degrees C/75% RH for 3 months. These results highlighted the feasibility of this coated tablet system containing TM, which may contribute to the successful treatment of irritable bowel syndrome.

Citing Articles

Evaluation of in vivo efficacy and toxicity of prednisolone-loaded hydrogel-based drug delivery device.

De A, Bhattacharya P, Datta S, Mukherjee A Int J Pharm Investig. 2013; 3(4):225-33.

PMID: 24350043 PMC: 3853763. DOI: 10.4103/2230-973X.121308.

References

Shah V, Tsong Y, Sathe P, Liu J . In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2. Pharm Res. 1998; 15(6):889-96. DOI: 10.1023/a:1011976615750. View

Costa P, Sousa Lobo J . Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13(2):123-33. DOI: 10.1016/s0928-0987(01)00095-1. View

Schmitz A, Lippold B . Aqueous ethyl cellulose dispersions containing plasticizers of different water solubility and hydroxypropyl methylcellulose as coating material for diffusion pellets. I. Drug release rates from coated pellets. Int J Pharm. 1999; 177(1):69-82. DOI: 10.1016/s0378-5173(98)00327-5. View

Appel-Dingemanse S, Hirschberg Y, Osborne S, Pommier F, McLeod J . Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur J Clin Pharmacol. 2001; 56(12):889-91. DOI: 10.1007/s002280000239. View

Rivkin A . Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin Ther. 2003; 25(7):1952-74. DOI: 10.1016/s0149-2918(03)80198-4. View

Zhou H, Khalilieh S, Lau H, GUERRET M, Osborne S, Alladina L . Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol. 1999; 39(9):911-9. DOI: 10.1177/00912709922008524. View

Fox M, Menne D, Stutz B, Fried M, Schwizer W . The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment Pharmacol Ther. 2006; 24(7):1017-27. DOI: 10.1111/j.1365-2036.2006.03090.x. View

Talley N, Camilleri M, Burton D, Thomforde G, Koch K, Rucker M . Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. Aliment Pharmacol Ther. 2006; 24(5):859-67. DOI: 10.1111/j.1365-2036.2006.03049.x. View

MALINOWSKI H, Marroum P, Uppoor V, Gillespie W, Ahn H, Lockwood P . Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol. 1997; 423:269-88. DOI: 10.1007/978-1-4684-6036-0_25. View

10.

Lerk C, Schoonen A, Fell J . Contact angles and wetting of pharmaceutical powders. J Pharm Sci. 1976; 65(6):843-7. DOI: 10.1002/jps.2600650611. View

11.

Appel-Dingemanse S, Lemarechal M, Kumle A, Hubert M, Legangneux E . Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol. 1999; 47(5):483-91. PMC: 2014177. DOI: 10.1046/j.1365-2125.1999.00936.x. View

12.

Appel S, Kumle A, Hubert M, Duvauchelle T . First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J Clin Pharmacol. 1997; 37(3):229-37. DOI: 10.1002/j.1552-4604.1997.tb04785.x. View

13.

Hadley S, Gaarder S . Treatment of irritable bowel syndrome. Am Fam Physician. 2005; 72(12):2501-6. View

14.

Swan S, Zhou H, Horowitz A, Alladina L, Hubert M, Appel-Dingemanse S . Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects. J Clin Pharmacol. 2003; 43(4):359-64. DOI: 10.1177/0091270003251823. View

15.

Hungin A, Whorwell P, Tack J, Mearin F . The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003; 17(5):643-50. DOI: 10.1046/j.1365-2036.2003.01456.x. View

16.

Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J . The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young. Aliment Pharmacol Ther. 2001; 15(7):937-44. DOI: 10.1046/j.1365-2036.2001.00973.x. View

17.

Ashford M, Fell J . Targeting drugs to the colon: delivery systems for oral administration. J Drug Target. 1994; 2(3):241-57. DOI: 10.3109/10611869408996806. View